ĸ	orm PTO-1449 U.S. Departm											Atty. Docket No. 65019-DA-PCT-US		Serial No. 09/754,004		
		5C32	.\										Applicant	s: Marc Feldmai	nn et al	••
•	3 201	os j	ᆈ	IN	FOI						OSURE CI s if necessar		Filing Date January 3		Group	
											U.S. PA	TENT DOCUMENTS	;			
	EATH	ner		Doc	umer	it Ni	umbe	er			Date	Name	Class	Subclass	Filing D	
	R	-		5	0	9	6	9	0	6	3/17/92	Mandell, et al.;			 	
_	Ĭ			4	6	9	5	4	5	9	9/22/87	Steinman, et al.;			ļ	_
-	+			5	6	5	6	2	7	2	8/6/97	Le, et al.;				
_	\top						2	0	6	6	3/26/96	Heinemann, et al.				
-	1			5	6	5	8	5	7	0	8/19/97	Newman, et al. (Exhibit 1);		·		
	_			5	5	8	0	8	7	3	12/3/96	Bianco, et al.;	-			
_				5			8	3	9	6	3/29/94	Kotzin, et al.		RE	CEI	VEI
_								<u> </u>	<u> </u>	╙	ļ	(Exhibit 2);				
				5	4	6	8	4	8	1	11/21/95	Sharma, et al.		ILIN	25	<u> </u>
_	\dashv		-	5	2	6	0	4	2	2	11/9/93	(Exhibit 3); Clark, et al.		301	D 0	2003
				ľ		۲	۲	Γ	 	۲		(Exhibit 4);		TEOUCE	ITCD	100010
				5	2	0	4	3	2	9	4/20/93	Ackerman, et al. (Exhibit 5)		TECH CE	HIER	1000/2 ~
_				5	9	9	4	5	1	0	11/30/99	Adair, et al.				
							L	<u> </u>		_		(Exhibit 6);				
	_			_			_	_								
			<u> </u>	<u> </u>		L	<u> </u>	<u></u>		l	FORFICN	L PATENT DOCUMEN	 NTS	<u> </u>	<u>. </u>	
_			<u> </u>	Do	cum	ent	Niii	mhe	r		Date	Country	Class	Subclass	Transl	ation
					CUIII	CIIC	114		-1		Date		0.000		Yes	No
			wo	9	2	0	7	0	7	6	4/30/92	PCT	-		105	
			wo	_	1	1	0	7	2	2	7/25/91	PCT	-			
			144 (פן	[1						1123171	μιτ				1
					<u> </u>	1	5	1	L	2	Ļ <u></u>	<u> </u>				<u></u>
_			wo	9	0	1	5	1	5	2	12/13/90	РСТ				
			WO EP	9	0	1	0	3	5	4	12/13/90 10/7/87	PCT EPO				
			WO EP AS	9	0 2 8	1 4 9	0 7	3	5 4 9	4	12/13/90 10/7/87 9/22/87	PCT EPO AS				
			WO EP AS CN	9 0 5	0 2 8 0	1 4 9	0 7 1	3	5	4	12/13/90 10/7/87 9/22/87 1/19/91	PCT EPO				
			WO EP AS CN DE	9 0 5 2	0 2 8 0	1 4 9 2 0	0 7 1 6	3 6 3 2	5 4 9 6	4 0 9	12/13/90 10/7/87 9/22/87	PCT EPO AS CN				
			WO EP AS CN DE	9 0 5 2	0 2 8 0	1 4 9 2 0	0 7 1 6	3 6 3 2	5 4 9 6	4 0 9	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90	PCT EPO AS CN DE				
			WO EP AS CN DE	9 0 5 2	0 2 8 0	1 4 9 2 0	0 7 1 6	3 6 3 2	5 4 9 6	4 0 9	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90	PCT EPO AS CN DE				
			WO EP AS CN DE	9 0 5 2	0 2 8 0	1 4 9 2 0	0 7 1 6	3 6 3 2	5 4 9 6	4 0 9	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90	PCT EPO AS CN DE				
			WO EP AS CN DE	9 0 5 2 4 2	0 2 8 0 0 2	1 4 9 2 0 4	0 7 1 6 6	3 6 3 2 5	5 4 9 6 6 6	4 0 9 9 9	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90	PCT EPO AS CN DE GB	te, Pertinent I	Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2	0 2 8 0 0 2 2	1 4 9 2 0 4 FH	0 7 1 6 6 6 ER	3 6 3 2 5 DO	5 4 9 6 6 6	4 0 9 9 9 9 ME	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315 (Ex	te, Pertinent I	Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2 Are	0 2 8 0 0 2 2 end,	1 4 9 2 0 4 4 W.1 .F. (0 7 1 6 6 6 P., e	3 6 3 2 5 DO t al.	5 4 9 6 6 6 6 7 (19)	4 0 9 9 9 9 14:	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315_(Exhibit 8);	te, Pertinent I	Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2 Are Bac Bar	0 2 8 0 0 2 2 end, ch, J	1 4 9 2 0 4 W.I .F. (0 7 1 6 6 6 ER P., e	3 6 3 2 5 5 DOO t al. (3)] al. (5 4 9 6 6 6 6 6 (19 (19 (199)	4 0 9 9 9 9 9 9 14::5) B	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315_Exhibit 8); tol. 34:747-755 (Exhib	te, Pertinent I khibit 7);	Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2 2 Bac Bar	O O O O O O O O O O O O O O O O O O O	1 4 9 2 0 4 W.I .F. (0 7 1 6 6 6 6 P., e (199 , et al.	3 6 3 2 5 5 DOO t al. (5 4 9 6 6 6 6 (19 (19 (1993) 94)	4 0 9 9 9 9 9 14:: 5) B	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315 (Exhibit 8); tol. 34:747-755 (Exhibit 10).	te, Pertinent I (xhibit 7);	Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2 2 Are Bac Bar Bre	O'cnd, Ch, J	1 4 9 2 0 4 4 W.I .F. (0 7 1 6 6 6 P., e (199 , et al.	3 6 3 2 5 5 t al. (3)]	5 4 9 6 6 6 6 (19 FiPs 1993	4 0 9 9 9 9 9 14:: 5) B Clin	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma . Exp. Immu Presse Med.	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315 (Exhibit 8); tol. 34:747-755 (Exhibit 10) 25:876-878, XP002048	te, Pertinent I (); (); (); (); (); (); (); (Pages, Etc.)		
			WO EP AS CN DE GB	9 0 5 2 4 2 Are Bac Bar Bol	O'cnd, Ch, J	1 4 9 2 0 4 4 W.I F. (, P., e a, C	0 7 1 6 6 6 P., e (199 , et al.	3 6 3 2 5 5 t al. (199 al. (199	5 4 9 6 6 6 6 (19 (19 (1993) 94)	4 0 9 9 9 9 9 14:: 5) B Clin	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma . Exp. Immu Presse Med. Rev. Allergy	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315 (Exhibit 8); tol. 34:747-755 (Exhibit 10:25:876-878, XP002048; v 11:543-559 (Exhibit 1:543-559 (Exhibit 1:543-559)	te, Pertinent I (whibit 7); (bit 9); (b); (3553; 11);			
			WO EP AS CN DE GB	9 0 5 2 4 2 Bac Bar Bre Bol	O'cnd, ch, J	1 4 9 2 0 4 W.I .F. (, P. n, e a, C	0 7 1 6 6 6 P., e (199 , et al.	3 6 3 2 5 5 t al. ((19 al. (199 al.	5 4 9 6 6 6 6 6 (19 FiPs 1994) (1993) (1993) (1994)	4 0 9 9 9 9 14::55 <u>B</u> Clin.	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma . Exp. Immu Presse Med. Rev. Allerge int. Arch. Al	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315_(Exhibit 8); tol. 34:747-755 (Exhibit 10) 25:876-878, XP002048 y 11:543-559 (Exhibit lergy Immunol. 104:112	te, Pertinent I khibit 7); sit 9); s); 3553; 11); 2-125 (Exhibi			
			WO EP AS CN DE GB	9 0 5 2 4 2 Bac Bac Bre Bol Cod Elli Fel	O' ond, ch, J rera nna logn oper ott, dma	1 4 9 2 0 4 4 .F. (, P. n, e a, C , K.	0 7 1 6 6 6 P., e (199 , et al. C., et M.,	3 6 3 2 5 5 t al. ((199 al. (t al.	5 4 9 6 6 6 6 (19 (199 (199 3) C (199 1. (1	4 0 9 9 9 9 14:: 5) <u>B</u> Clin 06) 1	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma . Exp. Immu Presse Med. Rev. Allerge int. Arch. Al	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315 (Exhibit 8); tol. 34:747-755 (Exhibit 10:25:876-878, XP002048; v 11:543-559 (Exhibit 1:543-559 (Exhibit 1:543-559)	te, Pertinent I khibit 7); sit 9); s); 3553; 11); 2-125 (Exhibi			
	12		WO EP AS CN DE GB	9 0 5 2 4 2 2 Bar Bre Bol Coo Elli Fel Frie	O 2 8 0 0 2 end, ch, J rera nna logn oper ott, dma sch es, J	FH W.I.F. (199, K., M.J., M.J.	0 7 1 6 6 6 6 P., e (199 t al. C., et D. (J., et M.,	3 6 3 2 5 5 t al. (3)] al. ((19) al. et a Bloc	5 4 9 6 6 6 6 (19 (199 (199 (199 (199 1. (1) od 7' 990	4 0 9 9 9 9 9 14:: 5) <u>B</u> Clin 06) <u>1</u> 14:: 993 30 J. J. J.	12/13/90 10/7/87 9/22/87 1/19/91 2/28/90 6/15/90 NTS (Includ Arthritis Rhe 213-216 (Ex r. J. Rheuma Exp. Immu Presse Med. Rev. Allerg nt. Arch. All) Ann. Rev.	PCT EPO AS CN DE GB ling Author, Title, Dateum. 33(3):305-315_(Exhibit 8); tol. 34:747-755 (Exhibit 10) 25:876-878, XP002048 y 11:543-559 (Exhibit lergy Immunol. 104:112	te, Pertinent I khibit 7); bit 9); b); 3553; 11); 2-125 (Exhibit Exhibit 13);			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 600. Declining through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Marc Feldmann

Applicants: Marc Feldmann, et al. Serial No.: 09/754,004

Filed: January 3, 2001

Exhibit A

m PTO-14	49 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 65019-DA-PCT-US	Serial No. 09/754,004						
(095)	INFORMATION DISCLOSURE CITATION	Applicants: Marc Feldmann et al							
2003	(Use several sheets if necessary)	Filing Date January 3, 2001	Group 644						
N. Ser	OTHER DOCUMENTS (Including Author, Title,		•						
6	Harris, et al. (1993) <u>Tibtech</u> 11:42-44;								
Ť	Herzog, C., et al. (1987) <u>Lancet</u> 2(8573):1461-1462 (Exhi	ibit 15);							
1	Hozzof, et al. (1987) <u>Lancet</u> 11:1461-1642								
	Kahan, B.D. (1992) <u>Curr. Opin. Immunol.</u> 4:553-560 (Exhibit 16);								
+	Kalden, J.R., et al. (1995) <u>Curr. Opin. Rheum.</u> 7: (3)191-1	97;							
	Littman, B.H., et al. (1995) Arthritis Rheum. 38:29-37 (Ex	xhibit 17);							
1-1-	Maini, R.N. (1996) J. Royal College of Physicians of Long	don_30(4):344-351;							
1	Maini, R.N. (1995) Arth. Rheum. Suppl. 38(9):S186 (Abst	tract 200);							
1	Matsumiya, G., et al. (1996) Transplant Proceed. 28(2):75	1-753 (Exhibit 18);							
	Moreland, L.W., et al. (1995) Arthritis Rheum. 38:1581-1:	588 (Exhibit 19);							
	Moreland, L.W., et al. (1996) J. Rheumatol. (Supplementa	al 44) 23:78-83 (Exhibit 20);	RECE						
	Piguet, et al. (1992) <u>Immunology</u> 77:510-514		JUN 2 5						
	Qin, S., et al. (1987) <u>Eur. J. Immunol.</u> 17:1159-1165 (Exh	nibit 21);	TECH CENTER						
	Richardson, C., et al. (1995) <u>Br. J. Clin. Prac.</u> 49:135-139	(Exhibit 22);							
	Sander, O., et al. (1995) Arthritis Rheum. 38:S266 (Abstra	act 678) (Exhibit 23);							
	Sosman, J.A., et al. (1993) <u>J. Pediatric Hematol. Oncol.</u> 15	5(2):185-195 (Exhibit 24);							
1	Stein, C.M., et al. (1994) Arthritis Rheum. 37:S252 (Exhib	bit 25);							
	Strober, et al. (1990) <u>Immunol. Reviews</u> 118:233-255;								
	Stuart, et al. (1986) <u>Laboratory Investigation</u> 34:1-13 (Exh	hibit 26);							
	Thorbecke, et al. (1992) <u>Proc. Natl. Acad. Sci. USA</u> 85:7375-7379;								
	Waldmann, T.A. (1991) <u>Science</u> 252:1657-1662;								
	Weinblatt, M.E., et al. (1994) Arthritis Rheum. 37:1492-1-	498 (Exhibit 27); and							
h	Decision on Appeal, issued March 21, 2003, for U.S. Seria	al No. 09/093,458, filed June 8	, 1998 (Exhibit 28).						
	DATE CONSIDERED 1/3/03								